Indication

Childhood hypophosphatasia

Childhood hypophosphatasia is a rare, inherited metabolic bone disorder defined by clinical onset between six months of age and adolescence, caused by loss-of-function variants in the ALPL gene. Read more about Childhood hypophosphatasia

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Childhood hypophosphatasia therapies.

Showing 1–1 of 1 drugs

STRENSIQ (asfotase alfa)

METABOLIC DISEASE ENZYME REPLACEMENT - HYPOPHOSPHATASIA·CHILDHOOD HYPOPHOSPHATASIA·+1
ALEXION PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Childhood hypophosphatasia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Childhood hypophosphatasia.

Childhood hypophosphatasia is a rare, inherited metabolic bone disorder defined by clinical onset between six months of age and adolescence, caused by loss-of-function variants in the ALPL gene.

This genetic defect leads to deficient activity of tissue-nonspecific alkaline phosphatase and the extracellular accumulation of inorganic pyrophosphate, an inhibitor of bone and dental mineralization.

Affected pediatric patients characteristically present with rickets-like skeletal deformities, short stature, delayed walking with a waddling gait, bone pain, and recurrent or poorly healing fractures.

A hallmark clinical feature is the premature loss of primary teeth with fully intact roots due to defective cementum formation, often accompanied by craniosynostosis and chronic musculoskeletal weakness.

Personalize your experience

Follow Childhood hypophosphatasia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it